Ostalo
DO THE BENEFITS OF ASPIRIN EXCEED THE RISK OF MAJOR BLEEDS IN PATIENTS TREATED FOR PRIMARY PREVENTION OF CEREBROVASCULAR AND CARDIOVASCULAR DISEASE?
PETAR KES
orcid.org/0000-0002-4501-4823
; Sveučilište u Zagrebu, Medicinski fakultet i Akademija medicinskih znanosti Hrvatske, Zagreb, Hrvatska
VANJA BAŠIĆ KES
; Klinički bolnički centar Sestre milosrdnice, Sveučilište u Zagrebu, Stomatološki fakultet, Klinika za neurologiju, Zagreb i Sveučilište Josip Juraj Strossmayer u Osijeku, Medicinski fakultet, Klinika za neurologiju, Osijek, Hrvatska
Sažetak
Daily aspirin use has long been heralded for its cardioprotective effects, particularly in at-risk individuals like those with diabetes mellitus. However, a signifi cant amount of research published in the last 5 years has called into question the benefits of aspirin for primary prevention of cardiovascular disease. Risk factors for gastrointestinal bleeding with aspirin use include higher dose and longer duration of use, history of gastrointestinal ulcers or upper gastrointestinal pain, bleeding disorders, renal failure, severe liver disease, and thrombocytopenia. Other factors that increase the risk of gastrointestinal or intracranial bleeding with low-dose aspirin use include concurrent anticoagulation or nonsteroidal anti-infl ammatory drug use, uncontrolled hypertension, male sex, and older age. Aspirin for primary cardiovascular disease prevention should be highly individualized, based on the benefi t-risk ratio assessment for the given patient.
Ključne riječi
aspirin; bleeding; cardiovascular disease; cerebrovascular disease; primary prevention; secondary prevention
Hrčak ID:
218968
URI
Datum izdavanja:
4.4.2019.
Posjeta: 1.464 *